ALEC Stock Analysis: Buy, Sell, or Hold?
ALEC - Alector, Inc. Common Stock
$1.51
-0.10 (-6.21%)
▼
5d:
-22.16%
30d:
-0.66%
90d:
-38.37%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Get Alerted When ALEC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALEC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ALEC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ALEC is currently trading at $1.51, which is considered oversold relative to its 30-day fair value range of $1.56 to $1.93.
Technical Outlook: Technically, ALEC is in a strong uptrend. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: ALEC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.10 (+105.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALEC is in a strong uptrend. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: ALEC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.10 (+105.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.56 -
$1.93
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.2%)
- BULLISH: Trading 105.3% below Wall St target ($3.10)
- CAUTION: 5-day price weakness (-22.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.56 -
$1.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.48
Resistance Level
$2.15
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.16
Wall Street Target
$3.10
(+105.3%)
Revenue Growth (YoY)
-71.5%
Earnings Growth (YoY)
-86.3%
Share & Embed Analysis
Last updated: July 13, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALEC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Grace Wong-Sarad
SELL
1820 shares
2026-04-16
Grace Wong-Sarad
SELL
1000 shares
2026-03-10
Grace Wong-Sarad
SELL
4079 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
